EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and Safety of Oral Spironolactone for Women With Acne Vulgaris: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials With Trial Sequential Analysis

Laura Ghanem iD, Najwaa Kirmani iD, Nathalia De León Fernández iD, María Paula Palacios-Ortiz iD, Juan David Rodríguez-Parra iD, Corina A Rusu iD

Journal of Cosmetic Dermatology · 2025

DOI: 10.1111/jocd.70411 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Laura Ghanem und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon. Hauptthemen laut MEDLINE: Spironolactone, Acne Vulgaris, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adult acne vulgaris is a chronic inflammatory skin condition that primarily affects females. Initial management includes topical and oral medications, but important limitations include ineffectiveness, nonadherence, and adverse effects. Spironolactone has shown good results in off‐label acne management.

Aims

We aim to conduct a systematic review and meta‐analysis exploring the safety and efficacy of oral spironolactone for females with acne.

Methods

We searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) comparing oral spironolactone in women with acne to placebo. The primary endpoint was the objective assessment of acne improvement. Secondary endpoints included subjective assessment and adverse events. Statistical analysis was performed using Review Manager 5.4. Heterogeneity was assessed with I 2 statistics.

Results

We included 563 patients from 5 RCTs, of which 251 (42.9%) received spironolactone. Objective assessment of acne improvement (OR 6.59; 95% 3.50–12.43; p < 0.00001; I 2 = 0%) was sixfold higher in the spironolactone group compared with placebo. Subjective assessment showed no difference between the two groups (OR 5.22; 95% 0.62–44.24; p < 0.13; I 2 = 85%). Menstrual irregularities (OR 1.09; 95% 0.37–3.25; p = 0.88; I 2 = 33%) and breast enlargement (OR 1.37; 95% 0.79–2.38; p = 0.26; I 2 = 0%) were nonsignificant in patients taking spironolactone. Trial sequential analysis (TSA) confirmed that the required sample size was reached, favoring spironolactone over placebo.

Conclusion

Our study suggests that oral spironolactone improves acne in female patients compared to placebo without increasing risks; thus, it should be elevated from “off‐label” use to an officially recommended standard of care. PROSPERO Registration CRD42024626984.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SpironolactoneAcne VulgarisMineralocorticoid Receptor AntagonistsHumansRandomized Controlled Trials as TopicFemaleAdministration, OralTreatment OutcomeAdult

Stichwörter der Autor:innen

acne vulgarisspironolactonewomen

Substanzen

SpironolactoneMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
  • Dow Medical College, Karachi, Pakistan.
  • Universidad de los Andes, Bogotá, Colombia.
  • Universidad San Francisco de Quito, Quito, Ecuador.
  • Pontificia Universidad Javeriana, Bogotá, Colombia.
  • Dermatology Department, University of Virginia, Charlottesville, Virginia, USA.

ORCID-Profile: Laura Ghanem, Najwaa Kirmani, Nathalia De León Fernández, María Paula Palacios-Ortiz, Juan David Rodríguez-Parra, Corina A Rusu

Zitieren

APA

Ghanem, L., Kirmani, N., De León Fernández, N., Palacios-Ortiz, M. P., Rodríguez-Parra, J. D., & Rusu, C. A. (2025). Efficacy and Safety of Oral Spironolactone for Women With Acne Vulgaris: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials With Trial Sequential Analysis. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70411

Vancouver

Ghanem L, Kirmani N, De León Fernández N, Palacios-Ortiz MP, Rodríguez-Parra JD, Rusu CA. Efficacy and Safety of Oral Spironolactone for Women With Acne Vulgaris: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials With Trial Sequential Analysis. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70411

BibTeX
@article{Ghanem2025,
  author = {Ghanem, Laura and Kirmani, Najwaa and De León Fernández, Nathalia and Palacios-Ortiz, María Paula and Rodríguez-Parra, Juan David and Rusu, Corina A},
  title = {Efficacy and Safety of Oral Spironolactone for Women With Acne Vulgaris: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials With Trial Sequential Analysis},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  doi = {10.1111/jocd.70411}
}
Kostenlos starten →